FARMINGDALE, N.Y., Jan. 29, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, recently attended the 2014 New York State Podiatric Clinical Conference held at the Marriott Marquis in New York City, NY from January 24th – 26th, 2014.
Misonix exhibited and presented the newest addition to its wound care line of devices, the SonicOne O.R. Ultrasonic Surgical Debridement System. The SonicOne O.R. is an innovative surgical device that allows surgeons to address the challenges chronic wounds present to them, the patient, and the health-care system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process. Use of the SonicOne O.R. system provides controlled tissue removal, decreased healing times, reduced bleeding and a reduction of biofilm.
The conference attracted more than 2,000 surgeons and wound care professionals and represents one of the largest podiatric meetings in the United States. Over the course of the three-day meeting, visitors to the Misonix exhibit had an opportunity to perform hands on trials of the SonicOne O.R. system. Leading wound care expert Wayne J. Caputo, DPM, Director of The Wound Care Center at Clara Maass Medical Center, a Barnabas Health member facility in Belleville, New Jersey, stated, "It's very simple. SonicOne O.R. represents the newest approach to healing wounds and offers a powerful solution to finally address biofilms, which are complex microbial communities of bacteria found in more than half of all chronic wounds and a key contributor to delay healing. SonicOne O.R., given the well appreciated antibacterial properties of ultrasound, is what we are now using in my center to debride all wounds. SonicOne O.R. is a complete tissue management system for both boney tissue and soft tissue and, as such, this is truly a revolutionary technology that every wound care center needs to be looking at right now."
Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, commented, "We had an extremely busy New York Clinical Conference with approximately 100 attendees visiting our exhibit seeking a product demonstration. The awareness of SonicOne O.R. is clearly increasing, peer-to-peer referrals are growing and hospitals are increasingly asking for evaluations in their operating rooms. When leading surgeons like Dr. Caputo at Barnabas Health's Clara Maass Wound Center make decisions to include SonicOne O.R. in their patient care protocols, this is an incredibly strong endorsement of our technology."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.